Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | CHIEF MEDICAL OFFICER | March 15, 2024 | March 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 | Direct | 203,000 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 203,000 · Balance 203,000 F1: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ventyx Biosciences, Inc.
Report date March 04, 2026 · Filed March 04, 2026
Section 16 reporting ended · disclosed 2026-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-04 · Disposition to issuer · Disposed 85,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2034-08-12 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Disposition to issuer · Disposed 350,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.
F2: At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement.
F3: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 4, 2026 16:15 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Disposition to issuerStock Option (Right to Buy) · Derivative | 350,000 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001922353-26-000002 · form4-03042026_090306.xml · derivative · entry 3 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2034-08-12 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3 · price: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. F3 · derivative.exercise_date: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 16:15 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Disposition to issuerStock Option (Right to Buy) · Derivative | 85,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001922353-26-000002 · form4-03042026_090306.xml · derivative · entry 2 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2035-01-02 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3 · price: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. F3 · derivative.exercise_date: At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 16:15 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Disposition to issuerCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001922353-26-000002 · form4-03042026_090306.xml · nonDerivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 16:30 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantCommon Stock | 3,000 | $1.03 | $3,090.00 |
DisclosureSEC source: 0001193125-25-288157 · ownership.xml · nonDerivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"), for the ESPP Purchase Period (as defined in the 2021 ESPP) of May 15, 2025 through November 14, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · date: The relevant Offering Period (as defined in the 2021 ESPP) ended, and the shares were acquired, on the Exercise Date (as defined in the 2021 ESPP) of November 17, 2025. F3 · price: In accordance with the 2021 ESPP, these shares were purchased based on 85% of the closing price on May 15, 2025. Read SEC document |
| May 15, 2025 Filed May 16, 2025 18:40 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantCommon Stock | 3,000 | $1.03 | $3,090.00 |
DisclosureSEC source: 0000950170-25-073812 · ownership.xml · nonDerivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"), for the ESPP Purchase Period (as defined in the 2021 ESPP) of November 15, 2024 through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · date: The relevant Offering Period (as defined in the 2021 ESPP) ended, and the shares were acquired, on the Exercise Date (as defined in the 2021 ESPP) of May 15, 2025. F3 · price: In accordance with the 2021 ESPP, these shares were purchased based on 85% of the closing price on May 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:50 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-25-000645 · form4-01032025_110132.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is January 2, 2025. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 16:48 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001415889-24-021189 · form4-08132024_080829.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest on the one year anniversary of the date of grant (the "Vesting Commencement Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:09 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 203,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-008491 · form4-03192024_080347.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,000 Underlying: Common Stock · 203,000 shares Expires not disclosed F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 1,638 | $0.97 | $1,588.86 |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · nonDerivative · entry 2 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,631 F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 6 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · nonDerivative · entry 1 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 15,813 | $0.91 | $14,389.83 |
DisclosureSEC source: 0001209191-24-000369 · doc4.xml · nonDerivative · entry 2 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,269 F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000369 · doc4.xml · derivative · entry 3 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-000369 · doc4.xml · nonDerivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan. Read SEC document |
| March 15, 2023 Filed Apr 5, 2023 19:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-023478 · doc4.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The stock option vests as of 1/48 of the total shares monthly beginning on April 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:22 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056613 · doc4.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:24 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-22-037053 · doc4.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on July 13, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 16:22 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Options (right to buy) · Derivative | 136,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-22-024938 · doc4.xml · derivative · entry 1 Forman Mark S · CIK 0001922353 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2032-04-17 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 18, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 5 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 4 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-09 F4 · derivative.exercise_date: The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 16, 2021 Filed Feb 13, 2024 19:34 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $10.84 | $0.00 |
DisclosureSEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 3 Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-08-15 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.